Together We Can...
|
|
“We are delighted and honoured to be the first customer for the MeridianIT PowerAI Vision platform, powered by IBM. This will enable OCB to dramatically speed up the development and commercialisation of precision tools to advance standards of care in personalised medicine for cancer. Vivolution has been fundamental in creating this collaboration with IBM and MeridianIT and to help solve a global healthcare challenge”
David Browning, CEO; Oxford Cancer Biomarkers
What we do
Commercial Innovation Partners who talk the language of start-ups and investors; specialising in growing emerging technology scale-ups operating in the IBM Partner Cloud and reaching customers who many only dream of.
Shaping healthtech, fintech & insurtech ideas in to viable business models in collaboration with strategic partners;
based on a lean startup and evidence based entrepreneur approach.
Shaping healthtech, fintech & insurtech ideas in to viable business models in collaboration with strategic partners;
based on a lean startup and evidence based entrepreneur approach.
WHO ARE WE?
Team of Business Advisers, with a 360 degree approach to SaaS business models, securing investment and routes-to-market
|
WHY ARE WE DIFFERENT?
Accustomed to rolling up our sleeves, talking the language of start-ups and Corporates; delivering results to your bottom line
|
WHY CHOOSE VIVOLUTION?
Emerging technology advocates with a proven track record of delivering success across domestic &
International markets |
A word from the founder
|
Mark RogerMark has worked at director level within the technology sector for over 15 years, with a background in commercialisation of Software technology companies. He has experience and expertise in SaaS business modelling, investment strategy, growth funding and wholesale business change. Mark has led M&A activity for a global software acquisition vehicle, led a technology investment fund and currently acts as director and non exec director for several tech start-ups.
|
"At IBM it's our objective to help bring solutions to market that improve health outcomes for patients. Working with likes of Vivolution, our Commercialisation Partner is critical to achieve this. Vivolution work with qualified scale-up’s and have not only introduced Oxford Cancer Biomarkers but continue to develop and support the relationship with IBM and Meridian IT. This collaboration showcases the potential of IBM’s platforms, including IBM PowerAI Vision, to support the rapid development and implementation of disruptive precision medicine innovation and resonates strongly with our focus on improving both the scope and quality of advanced personalised healthcare.”
Andreas Haimbock-Tichy, Director; Health & Life Sciences
